AI assistant
AVADEL PHARMACEUTICALS PLC — Director's Dealing 2024
Dec 11, 2024
31920_dirs_2024-12-10_333e4de6-9910-4e0a-84d1-d102fa3e2ec7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2024-12-06
Reporting Person: Divis Gregory J (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-12-06 | Ordinary Shares | P | 9598 | $9.9770 | Acquired | 9598 | Indirect |
| 2024-12-09 | Ordinary Shares | P | 402 | $9.82 | Acquired | 10000 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 159100 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.925 to $10.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2: These Ordinary Shares are held by the Gregory J. Divis Jr. Revocable Trust, of which the Reporting Person is trustee and beneficiary.